Ingenol methyl butenate gel (trade name: picato (R)) developed by Leo pharmaceutical company was approved by FDA on january25,2012 for the local treatment of actinic keratosis (AK) AK is a precancerous lesion caused by continuous sunlight, which can further evolve into squamous cell carcinoma (SCC). Studies have shown that 65% of SCC is caused by AK Ingenol methyl butenate is an active component extracted from the juice of the Australian plant Euphorbia peplus. It can induce apoptosis, but its specific mechanism of action in the treatment of AK is not clear Picato (R) is the first local gel approved for AK treatment. The course of treatment only takes 2 to 3 days. The results of 18 clinical studies completed so far show that after local use of picato (R) in patients with AK lesions in the head, face, trunk and limbs, the proportion of patients with disease severity reduced by more than 75% accounts for 60% ～ 68% and 44% ～ 55% respectively, and the proportion of patients with completely cleared lesions accounts for 37% ～ 47% and 28% ～ 42% respectively

    Available from Chengdu biopurify pharmaceuticals LtdingenolAnd ingenol methyl butenate, welcome to inquire.